One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Time to Abandon Renalism: Patients with Kidney Diseases Deserve More.
Gaut, Joseph P.
doi : 10.2215/CJN.0000000000000127
Volume 18(4) pgs. 419-548 April 2023
Continuous Glucose Monitoring: A Rapidly Evolving New Tool to Understand Pathophysiology and Enhance Clinical Care in CKD.
de Boer, Ian H. 1,2,3; Hirsch, Irl B. 2,3,4
Social Determinants of Health and Estimation of Kidney Function.
Bullock, Justin L. 1; Hall, Yoshio N. 1,2
Safety of Nirmatrelvir/Ritonavir in Dialysis Patients with COVID-19: The End of the Beginning?.
Yilmam, Osman A.; Leaf, David E.
Call for Greater Adoption of Recommended Standards during Cancer Drug Development to Improve Cancer Care with CKD.
Patel, Uptal D. 1,2
Safety of Alkalinization in CKD.
Melamed, Michal L. 1; Raphael, Kalani L. 2
Effect of Sodium Bicarbonate on Systolic Blood Pressure in CKD: A Systematic Review and Meta-Analysis.
Beynon-Cobb, Beverley 1,2; Louca, Panayiotis 2; Hoorn, Ewout J. 3; Menni, Cristina 2; Padmanabhan, Sandosh 4
doi : 10.2215/CJN.0000000000000119
Individuals with CKD are at a higher risk of cardiovascular morbidity and mortality. Acidosis is positively correlated with CKD progression and elevated systolic BP.
Social Determinants of Health and Their Impact on the Black Race Coefficient in Serum Creatinine-Based Estimation of GFR: Secondary Analysis of MDRD and CRIC Studies.
Eneanya, Nwamaka D. 1; Adingwupu, Ogechi M. 2; Kostelanetz, Sophia 3; Norris, Keith C. 4; Greene, Tom 5; Lewis, Julia B. 6; Beddhu, Srinivasan 7; Boucher, Robert 7; Miao, Shiyuan 2; Chaudhari, Juhi 2; Levey, Andrew S. 2; Inker, Lesley A. 2
doi : 10.2215/CJN.0000000000000109
The cause for differences in serum creatinine between Black and non-Black individuals incorporated into prior GFR-estimating equations is not understood.
Inclusion of Participants with CKD and Other Kidney-Related Considerations during Clinical Drug Development: Landscape Analysis of Anticancer Agents Approved from 2015 to 2019.
Butrovich, Morgan A. 1; Reaves, Allison C. 2; Heyward, Jamie 3; Moore, Thomas J. 3; Alexander, G. Caleb 3,4; Inker, Lesley A. 2; Nolin, Thomas D. 1,5
Clinical Outcomes and Vaccine Effectiveness for SARS-CoV-2 Infection in People Attending Advanced CKD Clinics: A Retrospective Provincial Cohort Study.
Roushani, Jian 1; Thomas, Doneal 2; Oliver, Matthew J. 2,3; Ip, Jane 2; Yeung, Angie 2; Tang, Yiwen 2; Brimble, Kenneth Scott 1,2; Levin, Adeera 4,5,6; Hladunewich, Michelle A. 2,3; Cooper, Rebecca 2; Blake, Peter G. 2,7
Frequency of Hypoglycemia Assessed by Continuous Glucose Monitoring in Advanced CKD.
Ushiogi, Yasuyuki 1; Kanehara, Hideo 2; Kato, Tamayo 1
Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019.
Hiremath, Swapnil 1; Blake, Peter G. 2,3; Yeung, Angie 3; McGuinty, Michaeline 4; Thomas, Doneal 3; Ip, Jane 3; Brown, Pierre Antoine 1; Pandes, Michael 5; Burke, Andrew 6; Sohail, Qazi Zain 2; To, Karen 7; Blackwell, Lindsay 8; Oliver, Matthew 9; Jain, Arsh K. 2; Chagla, Zain 10; Cooper, Rebecca 3,11
Effectiveness of Three Doses of mRNA COVID-19 Vaccines in the Hemodialysis Population during the Omicron Period.
Wing, Sara 1; Thomas, Doneal 2; Balamchi, Shabnam 3; Ip, Jane 2; Naylor, Kyla 4,5,6; Dixon, Stephanie N. 4,5,6; McArthur, Eric 5,6; Kwong, Jeffrey C. 5,7,8,9; Perl, Jeffrey 10; Atiquzzaman, Mohammad 11; Yeung, Angie 2; Yau, Kevin 1; Hladunewich, Michelle A. 1,2; Leis, Jerome A. 12; Levin, Adeera 11,13,14; Blake, Peter G. 2,15; Oliver, Matthew J. 1,2
A Simple Molecular Tool for the Assessment of Kidney Transplant Biopsies.
de Nattes, Tristan 1,2,3; Beadle, Jack 3; Toulza, Frederic 3; Candon, Edvin 1; Ruminy, Philippe 4; Francois, Arnaud 5; Bertrand, Dominique 1; Guerrot, Dominique 1; Drieux, Fanny 4,5; Roufosse, Candice 3; Candon, Sophie 2
Correction: Guidelines for Genetic Testing and Management of Alport Syndrome.
Peritoneal Dialysis in Critically Ill Patients: Time for a Critical Reevaluation?.
Al Sahlawi, Muthana 1; Ponce, Daniela 2; Charytan, David M. 3; Cullis, Brett 4,5; Perl, Jeffrey 6
Reinforcement Learning for Clinical Applications.
Khezeli, Kia 1,2; Siegel, Scott 1,2; Shickel, Benjamin 2,3; Ozrazgat-Baslanti, Tezcan 2,3; Bihorac, Azra 2,3; Rashidi, Parisa 1,2
Risk Prediction and Machine Learning: A Case-Based Overview.
Balczewski, Emily A. 1,2; Cao, Jie 2; Singh, Karandeep 3,4,5
Digital Health Transformers and Opportunities for Artificial Intelligence-Enabled Nephrology.
Shickel, Benjamin 1,2; Loftus, Tyler J. 1,3; Ren, Yuanfang 1,2; Rashidi, Parisa 1,4; Bihorac, Azra 1,2; Ozrazgat-Baslanti, Tezcan 1,2
Personalized Treatment of PLA2R-Related Membranous Nephropathy.
Fernandez-Juarez, Gema 1; Ronco, Pierre 2,3; Jha, Vivekanand 4,5,6
Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome.
Chan, Eugene Yu-hin 1,2; Yap, Desmond Yat-hin 3; Colucci, Manuela 4; Ma, Alison Lap-tak 1,2; Parekh, Rulan S. 5; Tullus, Kjell 6
doi : 10.2215/CJN.08570722
AB Rituximab is an established therapy in children with idiopathic nephrotic syndrome to sustain short- to medium-term disease remission and avoid steroid toxicities.
